Teva Pharmaceutical Industries Ltd. Q3 FY2026 earnings call

• Strategic Transformation Acceleration: CEO Richard Francis emphasized that Teva is successfully transitioning from a pure generics company to a biopharma entity. The "Pivot to Growth Strategy" launched in 2023 is delivering results, evidenced by rising gross margins and free cash flow.

• Innovative Portfolio Strength: The innovative portfolio grew 33% year-over-year. Key highlights include the FDA approval of Welltrusa for schizophrenia, strong momentum in Estedo and Adjovy, and the acquisition of BXCL501 from BioXcel to address acute agitation at home.

• Pipeline Milestones & Setbacks:

  • Wins: Approval of Welch Reuser (Welltrusa); FDA Fast Track designation for NTR15 (celiac disease); Positive data for Ecopipen (Tourette’s) leading to Priority Review; Progress in immunology programs including DARI and Anti-IL-15.
  • Setbacks: Discontinuation of the Phase 2 study for Emma Solman due to futility analysis. Management expressed disappointment but highlighted no safety concerns and noted the value of the data learned.

• Biosimilar Leadership: The biosimilar business is accelerating, with 3 out of 5 US biosimilars ranked #1. Management expects to achieve $800 million in biosimilar sales by 2026, expanding the portfolio to potentially 32 assets, including new partnerships like the one with Samsung.

• Financial Discipline & Capital Allocation: Teva achieved investment-grade status across all three major rating agencies. The company refinanced $4.9 billion in senior notes and opened EDS conversions for NYSE ordinary shares to broaden investor access. Net debt reduction remains a priority, with a target of net debt-to-EBITDA of 2x by end of 2027.

• Operational Efficiency: Gross margin expansion is driven by favorable product mix and structural cost savings. Management highlighted ongoing transformation programs aimed at achieving a 30% operating margin by 2027 through operational leverage and productivity improvements.

Total revenues were $4.4 billion, a 2% decline year-over-year, driven by generic headwinds but offset by strong innovative growth. Gross margin expanded to 58.7%, up 345 basis points, while EBITDA grew 7% and non-GAAP EPS increased 10%. Innovative products contributed significantly to the top-line resilience despite overall revenue contraction.

• Estedo (Austedo): Revenue reached $751 million, up 21% globally. The product is on track to exceed its $2.5 billion target one year ahead of schedule, with U.S. revenues up 21% and milligram dispenses growing 23%.
• Uzedi (Zepzelca): Revenue was $85 million, a substantial increase of 96% year-over-year. Commercial execution has doubled the franchise's market share from 5% to 10%, capturing significant volume from competitors.
• Adjov (Ajovy): Global revenue reached $269 million, up 61% year-over-year. U.S. revenues surged 89%, supported by volume growth and market share gains in both domestic and international markets.
• Welltrusa (Welch Reuser): Newly launched long-acting injectable for schizophrenia. While specific Q3 revenue figures are not disclosed due to early launch status, it is positioned as a key growth engine with a peak sales potential of $1.5 to $2 billion.
• Generics: Revenue declined 16%, primarily due to the loss of Generic Revlimid contribution. Excluding this impact, the generics business showed resilience with global growth of 1%.
• Biosimilars: Identified as a significant growth driver within the generics segment. The portfolio has expanded to 15 marketed products with 16 more in the pipeline, aiming to reach $800 million in sales by 2026, a year ahead of previous targets.

• Full-Year 2026 Revenue Guidance Raised: Increased to $16.7 billion – $17.0 billion, an upward revision of $175 million at the midpoint, driven by stronger-than-expected performance in innovative products.

• Product-Specific Guidance Increases:

  • Estedo: Raised to $2.55 billion – $2.65 billion (up $75 million).
  • Uzedi: Raised to $290 million – $310 million (up $20 million).
  • Adjovy: Raised to $930 million – $960 million (up $85 million).

• Profitability Metrics:

  • Operating Income: Expected range of $2.8 billion – $2.9 billion (Operating Margin 22.6% – 23.1%). Excluding IPR&D expenses, the adjusted operating margin is expected to be 27.8% – 28.2%.
  • Adjusted EBITDA: Expected range of $4.23 billion – $4.43 billion. Excluding IPR&D, this ranges from $5.1 billion – $5.3 billion.
  • Non-GAAP EPS: Raised to $1.92 – $2.11.
  • Free Cash Flow: Raised to $2.1 billion – $2.4 billion.

• Gross Margin Outlook: Full-year 2026 gross margin expected to remain in the range of 54.5% – 55.5%.

• Long-Term Trajectory: No detailed 2027 guidance provided, but management expects mid-single-digit revenue growth from 2023 to 2027. Operating margin is targeted to reach 30% by 2027, supported by portfolio shift and transformation efficiencies.

• Generic Revenue Erosion: Continued decline in generic revenues, particularly from the loss of Revlimid exclusivity, poses a headwind to total top-line growth, though partially offset by biosimilar expansion.

• IRA Implementation Impact: Anticipated negative impact on Austedo (Estedo) revenue in 2027 due to Inflation Reduction Act pricing negotiations and rebate structures. Management acknowledges significant exposure but cites strong fundamentals and portfolio diversification to mitigate this.

• Biosimilar Litigation and IP Risks: The biosimilar space involves complex intellectual property litigation (e.g., Janssen vs. Sympony, Genentech vs. Zolaire). Launch timing and legal outcomes can delay revenue recognition and affect market share.

• R&D Execution Risk: Discontinuation of the Emma Solman program highlights the inherent risk in clinical development. While management views this as a learning opportunity, continued failures could impact pipeline confidence.

• Commercial Execution Challenges: For new launches like Welltrusa, success depends heavily on securing Medicaid/Medicare coverage and physician adoption. Delays in formulary access could push revenue realization into later periods (e.g., second half of 2027).

Q: Analyst asked if Austedo can maintain $2.5B+ sales in 2027 despite IRA impacts and how gross margin expands to 58% without branded volume growth.

A: CFO Eli Kalif explained that margin expansion is driven by a favorable revenue mix shift toward innovative products and network optimization savings (~$700M), with ~100 bps from manufacturing efficiency and ~100 bps from innovation mix. CEO Richard Francis confirmed high confidence in Austedo reaching $2.5B next year, citing strong fundamentals offsetting IRA headwinds, and emphasized that the broader innovative portfolio (including Welltrusa and Ecopipen) will drive future growth and margin expansion beyond 2027.

Q: Analyst asked about the TAM for Welltrusa given olanzapine's metabolic side effects and whether it addresses non-compliant patients who tolerate the drug.

A: CEO Richard Francis stated that efficacy is the primary driver for severe schizophrenia patients, making olanzapine the gold standard. He argued that Welltrusa leverages this known efficacy via LAI format to improve adherence and reduce relapses. Dr. Eric Hughes added that since 20% of the market already uses oral olanzapine, the value proposition is bringing convenience and lower relapse rates to those already tolerating the molecule, rather than targeting intolerant patients.

Q: Analyst asked about the timeline for TL1A bispecifics and if Teva is exempt from generic tariffs under recent US government agreements.

A: Dr. Eric Hughes declined to provide specific timelines, noting that details will be shared at the upcoming R&D day, but confirmed Teva is a first-in-class leader in the TL1A space with potent, selective drugs. CEO Richard Francis clarified that there is no concluded agreement or exemption regarding generic tariffs; discussions are ongoing within a two-year timeframe, and Teva remains actively engaged in these negotiations.

Q: Analyst asked about M&A philosophy and R&D efficiency post-investment grade upgrade.

A: CEO Richard Francis stated that M&A and BD remain priorities but must drive long-term shareholder value and accretion, leveraging improved balance sheet flexibility without changing their disciplined capital allocation approach. Dr. Eric Hughes outlined the R&D philosophy as using "known science" to increase probability of success, speeding execution, and utilizing partnerships/AI to enhance bandwidth and funding efficiency.

Q: Analyst asked if Teva would pursue high-risk/high-return assets again after the Emma Solman futility, or if strategy shifted to de-risked assets.

A: CEO Richard Francis explained that the Emma Solman bet had low opportunity cost and high scientific understanding, justifying the risk then. However, going forward, the strategy shifts toward assets with higher probability of success to ensure consistent returns. He emphasized that while they won't avoid all risks, capital allocation will focus on thoughtful, de-risked investments that align with their goal of becoming a world-class biopharma company.